NMDA receptor
Assets acting on this target.
- Class
- NMDA receptor antagonist
The N-methyl-D-aspartate (NMDA) receptor is a subtype of glutamate-gated ion channel found throughout the central nervous system. Glutamate is the principal excitatory neurotransmitter in the brain, and NMDA receptors, when activated, allow calcium and other ions to flow into neurons, a step central to synaptic plasticity, learning, and memory. Under pathological conditions, however, excessive or dysregulated NMDA receptor activity can drive excitotoxicity, contributing to neuronal injury, and it has also been implicated in mood disorders, chronic pain, and movement disorders. NMDA receptor antagonists reduce this ion flow, either by blocking the channel pore directly, by occupying the glutamate or glycine binding sites, or by acting at specific accessory subunits (such as GluN2B) that shape the receptor's location and function. Depending on the degree and selectivity of blockade, this can produce rapid changes in mood circuitry, dampen pain signaling, or reduce abnormal motor circuit activity. Because NMDA receptors are essential for normal cognition, antagonism carries an inherent trade-off between therapeutic benefit and effects such as dissociation, sedation, or memory disturbance. This mechanism underlies interest in treatment-resistant depression, neuropathic pain, and adjunctive management of movement disorders, among other areas of active investigation.
Related mechanisms
NMDA receptor drugs compared
11 drugs, stage by indication
| Drug | Developer | Modality | Furthest stage | Stage by indication |
|---|---|---|---|---|
| Amantadine ER (Gocovri/ADS-5102)Gocovri | Adamas Pharmaceuticals, Supernus Pharmaceuticals | small molecule | Approved | Approved in Parkinson's Disease |
| EsketamineSpravato | Johnson & Johnson | small molecule | Approved | Approved in Major Depressive Disorder |
| ACP-211 | Acadia Pharmaceuticals | small molecule | Phase 2 | Phase 2 in Major Depressive Disorder |
| Arketamine (PRT042) | Sichuan Purity Pharmaceutical Technology | small molecule | Phase 2 | Phase 2 in Major Depressive Disorder |
| AV-101 | VistaGen Therapeutics | small molecule | Phase 2 | Phase 2 in Major Depressive Disorder |
| BI 1569912 | Boehringer Ingelheim | small molecule | Phase 2 | Phase 2 in Major Depressive Disorder |
| Blixeprodil | Gilgamesh Pharma | small molecule | Phase 2 | Phase 2 in Major Depressive Disorder |
| Esketamine (CLE-100) | Clexio Biosciences | small molecule | Phase 2 | Phase 2 in Major Depressive Disorder |
| Zelquistinel | Syndeio Biosciences | small molecule | Phase 2 | Phase 2 in Major Depressive Disorder |
| ALA-3000 | Alar Pharmaceuticals | small molecule | Phase 1 | Phase 1 in Major Depressive Disorder |
| SP-101 | Synphatec (Shanghai) Biopharmaceutical | small molecule | Phase 1 | Phase 1 in Major Depressive Disorder |